Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
December 12, 2025 Off

Independent Study Presented at American Society of Hematology (ASH) Annual Meeting Concludes Remestemcel-L Superior to Ruxolitinib in Clinical Outcomes as Treatment for SR-aGvHD

By GlobeNewswire

NEW YORK, Dec. 11, 2025 (GLOBE NEWSWIRE) — Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory…

December 12, 2025 Off

Cycle Pharmaceuticals to Acquire Applied Therapeutics

By GlobeNewswire

Applied Therapeutic’s lead drug candidate, govorestat, is a novel central nervous system penetrant Aldose Reductase Inhibitor for the treatment of…

December 12, 2025 Off

Serina Therapeutics Strengthens Leadership Team with Appointment of Dr. Joshua Thomas as VP, Head of Chemistry

By GlobeNewswire

HUNTSVILLE, Dec. 11, 2025 (GLOBE NEWSWIRE) — Serina Therapeutics, Inc. (“Serina” or the “Company”) (NYSE American: SER), a clinical-stage biotechnology company…

December 12, 2025 Off

Terns Announces Closing of Public Offering of Common Stock, Including Full Exercise of Underwriters’ Option to Purchase Additional Shares

By GlobeNewswire

FOSTER CITY, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Terns Pharmaceuticals, Inc. (“Terns” or the “Company”) (Nasdaq: TERN), a clinical-stage…

December 12, 2025 Off

BBOT Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

By GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — BridgeBio Oncology Therapeutics, Inc. (“BBOT”) (NASDAQ: BBOT), a clinical-stage biopharmaceutical…

December 12, 2025 Off

Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Shares

By GlobeNewswire

WALTHAM, Mass., Dec. 11, 2025 (GLOBE NEWSWIRE) — Dyne Therapeutics, Inc. (Nasdaq: DYN), a clinical-stage company focused on delivering functional…

December 12, 2025 Off

Crinetics Announces First Patient Dosed in Pivotal Adult Trial of Atumelnant in Congenital Adrenal Hyperplasia (CAH)

By GlobeNewswire

Phase 3 study builds on positive phase 2 results showing rapid and sustained reductions in key disease biomarkers and clinical…

December 12, 2025 Off

Tenaya Therapeutics Announces Proposed Public Offering

By GlobeNewswire

SOUTH SAN FRANCISCO, Calif., Dec. 11, 2025 (GLOBE NEWSWIRE) — Tenaya Therapeutics, Inc. (Nasdaq: TNYA), a clinical-stage biotechnology company with…

December 12, 2025 Off

Nusano Receives “Best Companies to Work For” Award from Utah Business

By GlobeNewswire

State’s top workplaces identified by employee survey dataWEST VALLEY CITY, Utah, Dec. 11, 2025 (GLOBE NEWSWIRE) — Nusano, physics company…

December 12, 2025 Off

Tenaya Therapeutics Reports Positive Interim Data from Cohort 1 of RIDGE™-1 Phase 1b/2 Clinical Trial of TN-401 Gene Therapy for Adults with PKP2-associated ARVC

By GlobeNewswire

TN-401 was Well Tolerated at 3E13 vg/kg dose Robust Transduction and Demonstrated Increases in PKP2 Protein Levels in First Two Patients…

Posts pagination

Previous 1 … 32 33 34 … 3,605 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine